Natixis Advisors
IMGN

Natixis Advisors’s Immunogen Inc IMGN Stock Holding History

Natixis Advisors’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-43,254
Closed -$1.28M – 1599
2023
Q4 		$1.28M Buy
43,254
+1,400
+3% +$27.9K ﹤0.01% 1137
2023
Q3 		$664K Sell
41,854
-10,718
-20% -$178K ﹤0.01% 1285
2023
Q2 		$992K Buy
+52,572
New +$621K ﹤0.01% 1162
2023
Q1 		– Sell
-54,165
Closed -$269K – 1515
2022
Q4 		$269K Sell
54,165
-428
-0.8% -$2.32K ﹤0.01% 1415
2022
Q3 		$261K Buy
54,593
+2,977
+6% +$15.7K ﹤0.01% 1403
2022
Q2 		$232K Sell
51,616
-589
-1% -$2.56K ﹤0.01% 1430
2022
Q1 		$248K Sell
52,205
-3,871
-7% -$21.4K ﹤0.01% 1402
2021
Q4 		$416K Buy
56,076
+17,713
+46% +$110K ﹤0.01% 1270
2021
Q3 		$218K Sell
38,363
-1,324
-3% -$7.65K ﹤0.01% 1303
2021
Q2 		$262K Sell
39,687
-1,265
-3% -$8.82K ﹤0.01% 1286
2021
Q1 		$331K Sell
40,952
-7,126
-15% -$58.2K ﹤0.01% 1222
2020
Q4 		$310K Sell
48,078
-189,106
-80% -$1.1M ﹤0.01% 1175
2020
Q3 		$854K Sell
237,184
-4,987
-2% -$20.1K 0.01% 972
2020
Q2 		$1.11M Sell
242,171
-31,673
-12% -$135K 0.01% 936
2020
Q1 		$934K Sell
273,844
-286
-0.1% -$1.25K 0.01% 922
2019
Q4 		$1.4M Sell
274,130
-13,020
-5% -$44.2K 0.01% 906
2019
Q3 		$695K Buy
287,150
+60,682
+27% +$161K 0.01% 997
2019
Q2 		$491K Buy
226,468
+112,320
+98% +$266K ﹤0.01% 1007
2019
Q1 		$309K Buy
114,148
+421
+0.4% +$1.82K ﹤0.01% 1033
2018
Q4 		$545K Buy
113,727
+4,917
+5% +$29.8K 0.01% 1007
2018
Q3 		$1.03M Sell
108,810
-25,494
-19% -$245K 0.01% 944
2018
Q2 		$1.31M Sell
134,304
-102,768
-43% -$1.08M 0.01% 875
2018
Q1 		$2.49M Sell
237,072
-43,789
-16% -$433K 0.02% 694
2017
Q4 		$1.8M Sell
280,861
-4,817
-2% -$29.7K 0.02% 736
2017
Q3 		$2.19M Sell
285,678
-7,553
-3% -$50.2K 0.02% 701
2017
Q2 		$2.08M Sell
293,231
-7,368
-2% -$33.7K 0.02% 687
2017
Q1 		$1.16M Buy
300,599
+14,629
+5% +$42.7K 0.01% 829
2016
Q4 		$583K Buy
285,970
+52,117
+22% +$105K 0.01% 927
2016
Q3 		$627K Sell
233,853
-60,437
-21% -$176K 0.01% 881
2016
Q2 		$906K Buy
294,290
+106,083
+56% +$665K 0.01% 806
2016
Q1 		$1.6M Buy
188,207
+33,377
+22% +$282K 0.02% 671
2015
Q4 		$2.1M Buy
154,830
+6,112
+4% +$75.2K 0.03% 582
2015
Q3 		$1.43M Sell
148,718
-4,803
-3% -$70.2K 0.02% 693
2015
Q2 		$2.21M Buy
153,521
+9,440
+7% +$104K 0.04% 597
2015
Q1 		$1.29M Buy
144,081
+51,894
+56% +$376K 0.02% 728
2014
Q4 		$562K Buy
92,187
+5,315
+6% +$48.6K 0.01% 898
2014
Q3 		$920K Buy
86,872
+15,336
+21% +$173K 0.02% 798
2014
Q2 		$848K Buy
71,536
+6,456
+10% +$81K 0.01% 856
2014
Q1 		$972K Buy
65,080
+8,145
+14% +$128K 0.02% 775
2013
Q4 		$835K Buy
56,935
+6,082
+12% +$93.5K 0.01% 773
2013
Q3 		$866K Sell
50,853
-1,161
-2% -$20.4K 0.02% 712
2013
Q2 		$863K Buy
+52,014
New +$843K 0.02% 700

Other funds holding IMGN

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Natixis Advisors's IMGN Position: Q1 2024 in Review

Natixis Advisors sold out of Immunogen Inc (IMGN) in Q1 2024, closing a stake of 43,254 shares — an estimated $1.28M sold.

Natixis Advisors first reported a position in IMGN in Q2 2013 and held it in 42 quarters. The position peaked at $2.49M in Q1 2018. 3 funds tracked by Wall St. Rank hold IMGN as of Q1 2024.

  • Natixis Advisors reported no remaining Immunogen Inc position as of Q1 2024 after selling out during the quarter.
  • Natixis Advisors sold 43,254 Immunogen Inc shares in Q1 2024, an estimated $1.28M.
  • Natixis Advisors first reported a position in Immunogen Inc in Q2 2013 and held it in 42 quarters.
  • Natixis Advisors's Immunogen Inc position peaked at $2.49M in Q1 2018.
  • 3 funds tracked by Wall St. Rank held Immunogen Inc as of Q1 2024.

Based on Natixis Advisors's 13F filing for Q1 2024, filed 25 Apr 2024.